IN8bio (INAB) Competitors $2.10 -0.23 (-9.87%) Closing price 04:00 PM EasternExtended Trading$2.10 0.00 (0.00%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. JATT, TLPH, XLO, GBIO, JSPR, DYAI, VRCA, XFOR, BCAB, and ADAPShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include JATT Acquisition (JATT), Talphera (TLPH), Xilio Therapeutics (XLO), Generation Bio (GBIO), Jasper Therapeutics (JSPR), Dyadic International (DYAI), Verrica Pharmaceuticals (VRCA), X4 Pharmaceuticals (XFOR), BioAtla (BCAB), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors JATT Acquisition Talphera Xilio Therapeutics Generation Bio Jasper Therapeutics Dyadic International Verrica Pharmaceuticals X4 Pharmaceuticals BioAtla Adaptimmune Therapeutics JATT Acquisition (NYSE:JATT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment. Do analysts rate JATT or INAB? IN8bio has a consensus target price of $180.00, suggesting a potential upside of 8,471.43%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00IN8bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is JATT or INAB more profitable? JATT Acquisition's return on equity of -49.58% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% IN8bio N/A -184.97%-126.75% Which has better earnings and valuation, JATT or INAB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AIN8bioN/AN/A-$30.44M-$9.11-0.23 Does the media favor JATT or INAB? In the previous week, IN8bio had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for JATT Acquisition. IN8bio's average media sentiment score of 0.95 beat JATT Acquisition's score of 0.00 indicating that IN8bio is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral IN8bio Positive Do insiders and institutionals hold more shares of JATT or INAB? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 15.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryIN8bio beats JATT Acquisition on 6 of the 10 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.53M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-0.2322.1185.3526.57Price / SalesN/A416.63582.95179.01Price / CashN/A47.1938.3262.20Price / Book0.3510.2112.726.53Net Income-$30.44M-$52.40M$3.30B$275.87M7 Day Performance-12.13%0.90%1.07%-1.40%1 Month Performance9.95%12.36%7.61%5.16%1 Year Performance-69.55%30.17%79.71%31.51% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.0325 of 5 stars$2.10-9.9%$180.00+8,471.4%-66.2%$9.53MN/A-0.2320Analyst ForecastGap DownJATTJATT AcquisitionN/A$2.41+14.8%N/A+9.0%$41.57MN/A0.003High Trading VolumeTLPHTalphera1.7522 of 5 stars$0.91+0.4%$5.00+449.5%+64.9%$41.32M$650K-2.2719News CoverageAnalyst ForecastXLOXilio Therapeutics2.0778 of 5 stars$0.86+8.4%$3.00+247.6%+6.1%$41.25M$15.00M-1.1470Analyst ForecastGap UpGBIOGeneration Bio3.8926 of 5 stars$5.98-0.3%$10.67+78.4%-73.7%$40.41M$19.89M-0.55150Analyst ForecastJSPRJasper Therapeutics3.403 of 5 stars$2.49+0.8%$25.63+929.1%-83.5%$40.15MN/A-0.4120Analyst ForecastDYAIDyadic International3.0158 of 5 stars$1.17+5.9%$6.00+415.0%+0.0%$39.81M$3.49M-6.137Positive NewsAnalyst ForecastVRCAVerrica Pharmaceuticals4.0053 of 5 stars$4.30+2.9%$80.00+1,760.5%-66.4%$39.48M$7.57M-0.5240Analyst ForecastXFORX4 Pharmaceuticals4.2272 of 5 stars$3.35-3.2%$34.17+919.9%-78.5%$39.47M$2.56M-0.2380Analyst ForecastGap DownBCABBioAtla0.5271 of 5 stars$0.69+3.3%N/A-49.0%$39.29M$11M-0.6360Positive NewsGap UpADAPAdaptimmune Therapeutics2.8198 of 5 stars$0.14-4.8%$1.35+865.5%-75.3%$38.96M$178.03M-0.22490News CoverageAnalyst ForecastOptions VolumeGap Down Related Companies and Tools Related Companies JATT Competitors TLPH Competitors XLO Competitors GBIO Competitors JSPR Competitors DYAI Competitors VRCA Competitors XFOR Competitors BCAB Competitors ADAP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
